In short
Clinical trials are investigating Tub-040 in people with difficult-to-treat cancer, including ovarian cancer and non-small cell lung cancer. These studies are looking at safety, tolerability, and early signs of benefit. They also aim to find the best dose for future research.
Key points
- Tub-040 is being studied in clinical trials for difficult-to-treat ovarian cancer and non-small cell lung cancer. One trial is Phase 1/2 and includes people with platinum-resistant high-grade ovarian cancer or relapsed/refractory adenocarcinoma non-small cell lung cancer. Another trial is Phase 1 and studies women with high-grade epithelial serous or endometrioid epithelial ovarian cancer. The main goals are to check safety, tolerability, and dose-limiting toxicities. Researchers also want to find the best dose for future development and, in one study, look for early signs of tumor response.
Trial overview
Two authorised clinical trials are investigating Tub-040 in people with certain hard-to-treat cancers. One study is testing Tub-040 in platinum-resistant high-grade ovarian cancer and relapsed/refractory adenocarcinoma non-small cell lung cancer. The other study is testing Tub-040 in women with high-grade epithelial serous or endometrioid epithelial ovarian cancer.
Who can join the studies
The first study includes adults with ovarian cancer that is resistant to platinum treatment, or people with non-small cell lung cancer that has come back or has not responded to treatment. The second study includes women with high-grade epithelial serous or endometrioid epithelial ovarian cancer. These are patient groups with cancers that often need new treatment options.
What the trials measure
The main safety measure in both trials is treatment-emergent adverse events (TEAEs), which means side effects that start or get worse after treatment begins. The studies also measure dose-limiting toxicities (DLTs), which are serious side effects that may stop doctors from increasing the dose. In the Phase 1/2 study, researchers also look at overall response rate (ORR), which shows how many patients have a tumor response based on central review.
Trial phases and study design
The first trial is a Phase 1/2 interventional study, so it starts by checking safety and dose, then moves to early testing of activity. Its Phase I part uses dose escalation, which means the dose is increased step by step to find the safest useful dose. The study aims to find the maximum tolerated dose (MTD) or the identified dose for optimization, and later the recommended Phase 2 dose for future development.
The second trial is a Phase 1 interventional study of Tub-040 given with standard chemotherapy. Its goal is to check safety and tolerability and to find the MTD, if one is observed. This means the study is mainly focused on finding a dose that can be studied further in future research.
Study sizes and status
The Phase 1/2 study plans to enroll 250 participants and is listed as authorised. The Phase 1 study plans to enroll 72 women and is also listed as authorised. Both studies are still in the early research stage, where the main question is whether the treatment can be given safely and how the dose should be set.
Why these trials matter
These trials are important because they focus on cancers that can be difficult to treat after standard therapy has stopped working. For patients, the key questions are whether Tub-040 can be given safely, what side effects may appear, and whether it shows early signs of helping the cancer. The results will help researchers decide whether Tub-040 should move into later studies.